Bouillaud E - Search Results

1

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.

Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. Brown DM, et al. Among authors: bouillaud e. Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. Am J Ophthalmol. 2022. PMID: 35038415 Free article. Clinical Trial.

2

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P. Beglinger C, et al. Among authors: bouillaud e. Endocrine. 2012 Oct;42(2):366-74. doi: 10.1007/s12020-012-9668-1. Epub 2012 Apr 21. Endocrine. 2012. PMID: 22527887 Clinical Trial.

3

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K. Petersenn S, et al. Among authors: bouillaud e. J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14. J Clin Pharmacol. 2012. PMID: 21673137 Clinical Trial.

4

Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.

Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N. Petersenn S, et al. Among authors: bouillaud e. Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24. Clin Ther. 2012. PMID: 22364824 Clinical Trial.

5

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

Dietrich H, Hu K, Ruffin M, Song D, Bouillaud E, Wang Y, Hasskarl J. Dietrich H, et al. Among authors: bouillaud e. Eur J Endocrinol. 2012 May;166(5):821-8. doi: 10.1530/EJE-11-0773. Epub 2012 Mar 1. Eur J Endocrinol. 2012. PMID: 22383336 Clinical Trial.

6

An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.

Shenouda M, Maldonado M, Wang Y, Bouillaud E, Hudson M, Nesheiwat D, Hu K. Shenouda M, et al. Among authors: bouillaud e. Am J Ther. 2014 May-Jun;21(3):164-73. doi: 10.1097/MJT.0b013e31824c3eb4. Am J Ther. 2014. PMID: 22713526 Clinical Trial.

7

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M. Golor G, et al. Among authors: bouillaud e. Drug Des Devel Ther. 2012;6:71-9. doi: 10.2147/DDDT.S29125. Epub 2012 Apr 19. Drug Des Devel Ther. 2012. PMID: 22573933 Free PMC article. Clinical Trial.

8

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.

Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH. Wolin EM, et al. Among authors: bouillaud e. Cancer Chemother Pharmacol. 2013 Aug;72(2):387-95. doi: 10.1007/s00280-013-2202-1. Epub 2013 Jun 14. Cancer Chemother Pharmacol. 2013. PMID: 23765178 Free PMC article. Clinical Trial.

9

Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.

Horsmans Y, Hu K, Ruffin M, Wang Y, Song D, Bouillaud E, Wang Y, Mazur D, Botha FP, Heuman DM. Horsmans Y, et al. Among authors: bouillaud e. J Clin Pharmacol. 2012 Apr;52(4):552-8. doi: 10.1177/0091270011400072. Epub 2012 Jan 26. J Clin Pharmacol. 2012. PMID: 22282526 Clinical Trial.

10

Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers.

Thudium K, Gallo J, Bouillaud E, Sachs C, Eddy S, Cheung W. Thudium K, et al. Among authors: bouillaud e. Clin Pharmacol. 2015 Jan 22;7:11-7. doi: 10.2147/CPAA.S73472. eCollection 2015. Clin Pharmacol. 2015. PMID: 25653564 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page